Differences in spending on provider-administered chemotherapy by site of care in Medicare

Yamini Kalidindi, Jeah (Kyoungrae) Jung, Roger Feldman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

OBJECTIVES: To compare Medicare spending on provider-administered chemotherapy in hospital outpatient departments (HOPDs) and physician offices after controlling for cancer type. STUDY DESIGN: Secondary data analysis. METHODS: We used 2010-2013 claims data for a random sample of Medicare fee-for-service beneficiaries who had cancer and received chemotherapy services either in physician offices or in HOPDs. We constructed 2 spending measures: (1) spending on chemotherapy drugs and (2) spending on chemotherapy administration. Each spending measure was the allowed payment, which includes both Medicare reimbursement and patient out-of-pocket spending. We compared the spending measures in the 2 care settings using regression analysis to control for certain patient risk factors, including cancer type. We also compared the number of chemotherapy and administration claims per beneficiary and spending per claim by cancer type to understand differences in utilization patterns in the 2 care settings. RESULTS: Risk-adjusted chemotherapy drug spending per beneficiary was $2451 lower in HOPDs compared with physician offices. Risk-adjusted chemotherapy administration spending was $322 higher in HOPDs than in physician offices. Patients in physician offices received chemotherapy drugs more frequently than those in HOPDs. However, the chemotherapy spending per claim line was higher in HOPDs than physician offices. CONCLUSIONS: Chemotherapy drug spending per Medicare beneficiary was lower in HOPDs than in physician offices, driven by less frequent use of chemotherapy in HOPDs. As the site of provider-administered chemotherapy shifts from physician offices to HOPDs, continuing assessment of cancer care spending by site of care is necessary.

Original languageEnglish (US)
Pages (from-to)328-333
Number of pages6
JournalThe American journal of managed care
Volume24
Issue number7
StatePublished - Jul 1 2018

Fingerprint

Medicare
Physicians' Offices
Hospital Departments
Drug Therapy
Outpatients
Neoplasms
Pharmaceutical Preparations
Fee-for-Service Plans
Health Expenditures
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Health Policy

Cite this

@article{ad87e745bd884fa59a2f10bca25c98e4,
title = "Differences in spending on provider-administered chemotherapy by site of care in Medicare",
abstract = "OBJECTIVES: To compare Medicare spending on provider-administered chemotherapy in hospital outpatient departments (HOPDs) and physician offices after controlling for cancer type. STUDY DESIGN: Secondary data analysis. METHODS: We used 2010-2013 claims data for a random sample of Medicare fee-for-service beneficiaries who had cancer and received chemotherapy services either in physician offices or in HOPDs. We constructed 2 spending measures: (1) spending on chemotherapy drugs and (2) spending on chemotherapy administration. Each spending measure was the allowed payment, which includes both Medicare reimbursement and patient out-of-pocket spending. We compared the spending measures in the 2 care settings using regression analysis to control for certain patient risk factors, including cancer type. We also compared the number of chemotherapy and administration claims per beneficiary and spending per claim by cancer type to understand differences in utilization patterns in the 2 care settings. RESULTS: Risk-adjusted chemotherapy drug spending per beneficiary was $2451 lower in HOPDs compared with physician offices. Risk-adjusted chemotherapy administration spending was $322 higher in HOPDs than in physician offices. Patients in physician offices received chemotherapy drugs more frequently than those in HOPDs. However, the chemotherapy spending per claim line was higher in HOPDs than physician offices. CONCLUSIONS: Chemotherapy drug spending per Medicare beneficiary was lower in HOPDs than in physician offices, driven by less frequent use of chemotherapy in HOPDs. As the site of provider-administered chemotherapy shifts from physician offices to HOPDs, continuing assessment of cancer care spending by site of care is necessary.",
author = "Yamini Kalidindi and Jung, {Jeah (Kyoungrae)} and Roger Feldman",
year = "2018",
month = "7",
day = "1",
language = "English (US)",
volume = "24",
pages = "328--333",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "7",

}

Differences in spending on provider-administered chemotherapy by site of care in Medicare. / Kalidindi, Yamini; Jung, Jeah (Kyoungrae); Feldman, Roger.

In: The American journal of managed care, Vol. 24, No. 7, 01.07.2018, p. 328-333.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differences in spending on provider-administered chemotherapy by site of care in Medicare

AU - Kalidindi, Yamini

AU - Jung, Jeah (Kyoungrae)

AU - Feldman, Roger

PY - 2018/7/1

Y1 - 2018/7/1

N2 - OBJECTIVES: To compare Medicare spending on provider-administered chemotherapy in hospital outpatient departments (HOPDs) and physician offices after controlling for cancer type. STUDY DESIGN: Secondary data analysis. METHODS: We used 2010-2013 claims data for a random sample of Medicare fee-for-service beneficiaries who had cancer and received chemotherapy services either in physician offices or in HOPDs. We constructed 2 spending measures: (1) spending on chemotherapy drugs and (2) spending on chemotherapy administration. Each spending measure was the allowed payment, which includes both Medicare reimbursement and patient out-of-pocket spending. We compared the spending measures in the 2 care settings using regression analysis to control for certain patient risk factors, including cancer type. We also compared the number of chemotherapy and administration claims per beneficiary and spending per claim by cancer type to understand differences in utilization patterns in the 2 care settings. RESULTS: Risk-adjusted chemotherapy drug spending per beneficiary was $2451 lower in HOPDs compared with physician offices. Risk-adjusted chemotherapy administration spending was $322 higher in HOPDs than in physician offices. Patients in physician offices received chemotherapy drugs more frequently than those in HOPDs. However, the chemotherapy spending per claim line was higher in HOPDs than physician offices. CONCLUSIONS: Chemotherapy drug spending per Medicare beneficiary was lower in HOPDs than in physician offices, driven by less frequent use of chemotherapy in HOPDs. As the site of provider-administered chemotherapy shifts from physician offices to HOPDs, continuing assessment of cancer care spending by site of care is necessary.

AB - OBJECTIVES: To compare Medicare spending on provider-administered chemotherapy in hospital outpatient departments (HOPDs) and physician offices after controlling for cancer type. STUDY DESIGN: Secondary data analysis. METHODS: We used 2010-2013 claims data for a random sample of Medicare fee-for-service beneficiaries who had cancer and received chemotherapy services either in physician offices or in HOPDs. We constructed 2 spending measures: (1) spending on chemotherapy drugs and (2) spending on chemotherapy administration. Each spending measure was the allowed payment, which includes both Medicare reimbursement and patient out-of-pocket spending. We compared the spending measures in the 2 care settings using regression analysis to control for certain patient risk factors, including cancer type. We also compared the number of chemotherapy and administration claims per beneficiary and spending per claim by cancer type to understand differences in utilization patterns in the 2 care settings. RESULTS: Risk-adjusted chemotherapy drug spending per beneficiary was $2451 lower in HOPDs compared with physician offices. Risk-adjusted chemotherapy administration spending was $322 higher in HOPDs than in physician offices. Patients in physician offices received chemotherapy drugs more frequently than those in HOPDs. However, the chemotherapy spending per claim line was higher in HOPDs than physician offices. CONCLUSIONS: Chemotherapy drug spending per Medicare beneficiary was lower in HOPDs than in physician offices, driven by less frequent use of chemotherapy in HOPDs. As the site of provider-administered chemotherapy shifts from physician offices to HOPDs, continuing assessment of cancer care spending by site of care is necessary.

UR - http://www.scopus.com/inward/record.url?scp=85060174248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060174248&partnerID=8YFLogxK

M3 - Article

C2 - 30020752

AN - SCOPUS:85060174248

VL - 24

SP - 328

EP - 333

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 7

ER -